| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Clinical Investigations |
1 Department of Nuclear Medicine, M.D. Anderson Cancer Center, University of Texas, Houston, Texas
2 Department of Diagnostic Radiology, M.D. Anderson Cancer Center, University of Texas, Houston, Texas
3 Department of Biostatistics, M.D. Anderson Cancer Center, University of Texas, Houston, Texas
Gastrointestinal stromal tumors (GISTs) are gaining the interest of researchers because of impressive metabolic response to the targeted molecular therapeutic drug imatinib mesylate. Initial reports suggest an impressive role for 18F-FDG PET in follow-up of therapy for these tumors. However, the role of 18F-FDG PET versus that of CT has not been established. Therefore, we compared the roles of 18F-FDG PET and CT in staging and evaluation of early response to imatinib mesylate therapy in recurrent or metastatic GIST. Methods: The study included 54 patients who underwent 18F-FDG PET and CT scans within 3 wk before initiation of imatinib mesylate therapy. Forty-nine of these patients underwent repeat scans 2 mo after therapy. The numbers of sites or organs containing lesions on 18F-FDG PET and CT scans were compared. Corresponding lesions on 18F-FDG PET and CT scans or those confirmed to be malignant in appearance by other imaging modalities or on follow-up were considered true positives. Lesions seen on 18F-FDG PET or CT scans but not seen or confirmed to be of benign appearance with other imaging modalities or on follow-up were considered false positives. Measurements of the maximum standard uptake value (SUV) on 18F-FDG PET scans and tumor size on CT scans were used for quantitative evaluation of early tumor response to therapy. Results: A total of 122 and 114 sites and/or organs were involved on pretherapy 18F-FDG PET and CT scans, respectively. The sensitivity and positive predictive values (PPVs) for CT were 93% and 100%; whereas these values for 18F-FDG PET were 86% and 98%. However, the differences between these values for CT and 18F-FDG PET were not statistically significant (P = 0.27 for sensitivity and 0.25 for PPV). This suggests comparable performance of 18F-FDG PET and CT in staging GISTs. Repeat scans at 2 mo after therapy showed agreement between 18F-FDG PET and CT scans in 71.4% of patients (57.1% having a good response to therapy and 14.3% lacking a response). Discrepant results between 18F-FDG PET and CT were recorded for 28.6% of the patients. 18F-FDG PET predicted response to therapy earlier than did CT in 22.5% of patients during a longer follow-up interval (4–16 mo), whereas CT predicted lack of response to therapy earlier than 18F-FDG PET in 4.1%. One patient did not undergo long-term follow-up. These findings suggest that 18F-FDG PET is superior to CT in predicting early response to therapy in recurrent or metastatic GIST patients. Conclusion: The performances of 18F-FDG PET and CT are comparable in staging GISTs before initiation of imatinib mesylate therapy. However, 18F-FDG PET is superior to CT in predicting early response to therapy. Thus, 18F-FDG PET is a better guide for imatinib mesylate therapy.
Key Words: gastrointestinal stromal tumors • PET • imatinib mesylate
This article has been cited by other articles:
|
|
 |
|
  N. Lassau, S. Koscielny, L. Albiges, L. Chami, B. Benatsou, M. Chebil, A. Roche, and B. J. Escudier Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography Clin. Cancer Res., February 15, 2010; 16(4): 1216 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Ng, D. L. Raunig, E. F. Jackson, E. A. Ashton, F. Kelcz, K. B. Kim, R. Kurzrock, and T. M. McShane Reproducibility of Perfusion Parameters in Dynamic Contrast-Enhanced MRI of Lung and Liver Tumors: Effect on Estimates of Patient Sample Size in Clinical Trials and on Individual Patient Responses Am. J. Roentgenol., February 1, 2010; 194(2): W134 - W140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Doubrovin, T. Kochetkova, E. Santos, D. R. Veach, P. Smith-Jones, N. Pillarsetty, J. Balatoni, W. Bornmann, J. Gelovani, and S. M. Larson 124I-Iodopyridopyrimidinone for PET of Abl Kinase-Expressing Tumors In Vivo J. Nucl. Med., January 1, 2010; 51(1): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Le Cesne, M. Van Glabbeke, J. Verweij, P. G. Casali, M. Findlay, P. Reichardt, R. Issels, I. Judson, P. Schoffski, S. Leyvraz, et al. Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial J. Clin. Oncol., August 20, 2009; 27(24): 3969 - 3974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Contractor and E. O. Aboagye Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Laing, M. A. Walter, D. O. Campbell, H. R. Herschman, N. Satyamurthy, M. E. Phelps, J. Czernin, O. N. Witte, and C. G. Radu Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography PNAS, February 24, 2009; 106(8): 2847 - 2852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Prior, M. Montemurro, M.-V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A. B. Delaloye, et al. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor J. Clin. Oncol., January 20, 2009; 27(3): 439 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Spratlin, N. J. Serkova, and S. G. Eckhardt Clinical Applications of Metabolomics in Oncology: A Review Clin. Cancer Res., January 15, 2009; 15(2): 431 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Van den Abbeele The Lessons of GIST--PET and PET/CT: A New Paradigm for Imaging Oncologist, April 1, 2008; 13(suppl_2): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Holdsworth, R. D. Badawi, J. B. Manola, M. F. Kijewski, D. A. Israel, G. D. Demetri, and A. D. Van den Abbeele CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor Am. J. Roentgenol., December 1, 2007; 189(6): W324 - W330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott The expanding role of PET technology in the management of patients with colorectal cancer Ann. Onc., November 1, 2007; 18(11): 1774 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Utikal, S. Ugurel, H. Kurzen, P. Erben, A. Reiter, A. Hochhaus, T. Nebe, R. Hildenbrand, U. Haberkorn, S. Goerdt, et al. Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses Arch Dermatol, June 1, 2007; 143(6): 736 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Riedl, T. Akhurst, S. Larson, S. F. Stanziale, S. Tuorto, A. Bhargava, H. Hricak, D. Klimstra, and Y. Fong 18F-FDG PET Scanning Correlates with Tissue Markers of Poor Prognosis and Predicts Mortality for Patients After Liver Resection for Colorectal Metastases J. Nucl. Med., May 1, 2007; 48(5): 771 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber and R. Figlin Monitoring Cancer Treatment with PET/CT: Does It Make a Difference? J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lassau, M. Lamuraglia, L. Chami, J. Leclere, S. Bonvalot, P. Terrier, A. Roche, and A. Le Cesne Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am. J. Roentgenol., November 1, 2006; 187(5): 1267 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Meyer, S. Aliberti, G. Grignani, M. Aglietta, M. E. Juweid, and B. D. Cheson Positron-emission tomography in cancer therapy. N. Engl. J. Med., May 4, 2006; 354(18): 1958 - 1960. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Warakaulle and F. Gleeson MDCT Appearance of Gastrointestinal Stromal Tumors After Therapy with Imatinib Mesylate Am. J. Roentgenol., February 1, 2006; 186(2): 510 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
